<DOC>
	<DOCNO>NCT02589639</DOCNO>
	<brief_summary>This multi-center , randomise , double-blind , placebo-controlled , parallel-group , efficacy safety study empagliflozin add-on insulin Japanese patient Type 2 Diabetes Mellitus insufficient glycaemic control</brief_summary>
	<brief_title>Efficacy Safety Study Empagliflozin add-on Insulin Japanese Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criterion : Diagnosis type 2 diabetes mellitus Patients diet exercise regimen pretreated insulin therapy alone combination 1 oral antidiabetic drug least 12 week prior screen Fasting Cpeptide must &gt; 0.5 ng/mL HbA1c screening Patients treated insulin alone must &gt; =7.5 % &lt; =10.0 % HbA1c Patients treat insulin 1 OAD must &gt; =7.0 % &lt; =9.5 % screening , &gt; =7.5 % &lt; =10.0 % placebo runin period Age inform consent must &gt; =20 &lt; 75 year BMI screening must &gt; 22 &lt; =40 kg/m2 Further inclusion criterion apply Exclusion criterion : Patients experience uncontrolled hyperglycaemia randomization Patients treat sulfonylurea whose dose half daily maximum approval dose , GLP1 analogue , thiazolidinedione SGLT2 inhibitor Patients recent cardiovascular and/or stroke event Patients hepatic and/or renal dysfunction Patients receive antiobesity drug treatment lead unstable body weight Patients know allergy hypersensitivity insulin and/or empagliflozin Premenopausal woman nurse pregnant Further exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>